Journal article
Girdin (GIV) expression as a prognostic marker of recurrence in mismatch repair-proficient stage II colon cancer
P Ghosh, J Tie, A Muranyi, S Singh, P Brunhoeber, K Leith, R Bowermaster, Z Liao, Y Zhu, B LaFleur, B Tran, J Desai, I Jones, M Croxford, R Jover, A Goel, P Waring, S Hu, V Teichgraber, UP Rohr Show all
Clinical Cancer Research | Published : 2016
Abstract
Purpose: Prognostic markers that identify patients with stage II colon cancers who are at the risk of recurrence are essential to personalize therapy. We evaluated the potential of GIV/Girdin as a predictor of recurrence risk in such patients. Experimental Design: Expression of full-length GIV was evaluated by IHC using a newly developed mAb together with a mismatch repair (MMR)-specific antibody panel in three stage II colon cancer patient cohorts, that is, a training (n = 192), test (n = 317), and validation (n = 181) cohort, with clinical follow-up data. Recurrence risk stratification models were established in the training cohort of T3, proficient MMR (pMMR) patients without chemotherapy..
View full abstractGrants
Awarded by National Institutes of Health
Funding Acknowledgements
This work was supported by Ventana Medical Systems, Inc., the NIH (R01CA160911 and R01 CA100768, to P. Ghosh; R01 CA72851, CA 181572, and U01 CA187956, to A. Goel), and seed grant from the Moores Cancer Center (P30CA23100, to P. Ghosh) and the Baylor Research Institute (to A. Goel).